Selexipag Patent Expiration
Selexipag is Used for treating pulmonary arterial hypertension. It was first introduced by Actelion Pharmaceuticals Us Inc
Selexipag Patents
Given below is the list of patents protecting Selexipag, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Uptravi |
US10821108 (Pediatric) | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide | Jun 01, 2037 | Actelion |
| Uptravi |
US10828298 (Pediatric) | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy]-N-(Methylsulfonyl)Acetamide | Jun 01, 2037 | Actelion |
| Uptravi | US10821108 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | Dec 01, 2036 | Actelion |
| Uptravi | US10828298 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide | Dec 01, 2036 | Actelion |
| Uptravi |
US8791122 (Pediatric) | Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide And Method For Producing The Same | Feb 01, 2031 | Actelion |
| Uptravi |
US9284280 (Pediatric) | Use Of Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide | Dec 25, 2030 | Actelion |
| Uptravi | US8791122 | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same | Aug 01, 2030 | Actelion |
| Uptravi | US9284280 | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | Jun 25, 2030 | Actelion |
| Uptravi |
US9173881 (Pediatric) | Therapeutic Compositions Containing Macitentan | Feb 12, 2030 | Actelion |
| Uptravi | US9173881 | Therapeutic compositions containing macitentan | Aug 12, 2029 | Actelion |
| Uptravi |
US7205302 (Pediatric) | Heterocyclic Compound Derivatives And Medicines | Apr 30, 2027 | Actelion |
| Uptravi | US7205302 | Heterocyclic compound derivatives and medicines | Oct 31, 2026 | Actelion |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Selexipag's patents.
Latest Legal Activities on Selexipag's Patents
Given below is the list recent legal activities going on the following patents of Selexipag.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jan, 2026 | US8791122 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828298 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10821108 |
| Court Processing Terminated | 02 Apr, 2024 | US7205302 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284280 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Apr, 2023 | US9173881 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jan, 2022 | US8791122 |
| Patent Term Extension Certificate Critical
| 12 Nov, 2021 | US7205302 |
| Notice of Final Determination -Eligible | 09 Mar, 2021 | US7205302 |
| Case Docketed to Examiner in GAU Critical
| 06 Jan, 2021 | US7205302 |
Selexipag's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Selexipag:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension | Actelion | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension | Actelion | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets | Humanis Saglık Anonim Sirketi | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis | Actelion | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |